# DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

> clinical trial · VERIFIED · 2026-06-23

Status: ACTIVE_NOT_RECRUITING · Sponsor: Boehringer Ingelheim · Condition: Neuroendocrine Neoplasms

- Company: Boehringer Ingelheim
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06132113

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.